SABCS 2015

Trastuzumab-containing chemotherapy regimens offer superior survival to in HER2-positive early breast cancer.

Evidence-based clinical practice has evolved and the search for how best to blockade the HER2 receptor in HER2+ breast cancer continues.

Trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer is associated with superior long-term disease-free survival.

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Whole exome sequencing analysis reveals considerable mutational heterogeneity among cells within lobular carcinoma in situ (LCIS) lesions.

Fibroblast growth factor receptor 1 (FGFR1) gene and ligand co-amplification is associated with endocrine resistance in breast cancer cells.

Letrozole and anastrozole have similar survival efficacy and safety profiles in hormone receptor-positive (HR+), node-positive breast cancer.

A short sequential regimen of neoadjuvant chemotherapy offers comparable pathological complete response in node-positive breast cancer.

Capecitabine improved disease-free survival (DFS) among women with residual HER2-negative breast cancer after neoadjuvant chemotherapy.

Circulating tumor cells (CTCs) 2 years after chemotherapy are associated with poor survival rates in breast cancer.